Study summary

Half of men on enzalutamide were alive 8 years later

ENZAMET trial (8-year results) · 1,125 men, phase 3 · Published August 2026, Annals of Oncology

50%alive at 8 years, vs 40% with the older drug

What was tested

Enzalutamide against an older antiandrogen, both with testosterone suppression, for metastatic hormone-sensitive prostate cancer.

What they found

What it means

Shows how far survival has come with modern hormone therapy started at diagnosis.

Ann Oncol, via PubMed ↗ Trial record NCT02446405 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.